RxDoctor Payments Data

Wendy Mercier

Acute Care · Norristown, PANPI 1487077129

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $4,247 of the $6,569 with a category attached, or 64.7%. Abbott accounts for 92.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $3,703 and has fallen 94.3% since, to $211 in 2025. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,569in general payments, 2019–2025

Across 63 payments — averaging $104.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Boehringer Ingelheim$318
  • Novartis$95
  • Tactile Systems Technology Inc$22
  • Heartflow, Inc.$17
  • Inspire Medical Systems, Inc.$16

What the payments were for

  • Travel & lodging$4,24765%
  • Food & beverage$2,32235%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,569 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,726
Medicare patients
99
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$29,369
JardianceEmpagliflozin12$7,398
Valsartan23$1,666
Losartan Potassium42$554
Metoprolol Succinate34$433
Carvedilol19$284
Amlodipine Besylate54$274
Rosuvastatin Calcium14$258
Lisinopril34$257
Bumetanide15$239
Atorvastatin Calcium29$238
Hydralazine Hcl11$191
ClopidogrelClopidogrel Bisulfate15$183
Doxazosin Mesylate16$143
Spironolactone21$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$318$7,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Norristown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →